Index of /wp-content/uploads/2025/08

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[IMG]08-04-25_smartphone.jpeg2025-08-03 17:18 99K 
[IMG]08-05-25_multiple-sclerosis.jpeg2025-08-04 20:27 100K 
[IMG]08-05-25_suicide.jpeg2025-08-05 13:28 68K 
[IMG]08-07-25_ADHD.jpeg2025-08-06 14:37 91K 
[IMG]08-08-25_abuse.jpeg2025-08-07 21:13 58K 
[IMG]08-11-25_AI.jpeg2025-08-08 21:38 154K 
[IMG]08-12-25_stroke.jpeg2025-08-11 14:27 85K 
[IMG]08-13-25_schizophrenia.jpeg2025-08-12 16:19 122K 
[IMG]08-14-25_suicide.jpeg2025-08-13 14:10 77K 
[IMG]08-15-25_talking.jpeg2025-08-13 19:06 111K 
[IMG]08-18-25_adhd.jpeg2025-08-15 19:15 153K 
[IMG]08-19-25_postpartum.jpeg2025-08-19 14:12 98K 
[IMG]08-19-25_sensitivity.jpeg2025-08-18 15:49 75K 
[IMG]08-21-25_memory.jpeg2025-08-21 17:26 64K 
[IMG]08-22-25_memories.jpeg2025-08-21 21:21 155K 
[IMG]08-25-25_sleep.jpeg2025-08-22 17:48 59K 
[IMG]08-26-25_Rhythm.jpeg2025-08-24 18:14 86K 
[IMG]08-27-25_schizophrenia.jpeg2025-08-26 22:54 636K 
[IMG]08-28-25_political.jpeg2025-08-28 18:48 213K 
[IMG]08-29-25_cannabis.jpeg2025-08-29 17:02 59K 
[IMG]24m15614-f1.png2025-08-08 13:21 31K 
[IMG]24m15614-f2.png2025-08-08 13:21 69K 
[ ]ASCERTAIN-TRD-Aripiprazole-rTMS-Augmentation-vs-Switching-to-Venlafaxine-Quality-of-Life-JCP-24m15614-SM.pdf2025-08-09 22:16 201K 
[ ]ASCERTAIN-TRD-Aripiprazole-rTMS-Augmentation-vs-Switching-to-Venlafaxine-Quality-of-Life-JCP-24m15614.pdf2025-08-09 22:16 3.6M 
[IMG]C1_PCC-27-4.png2025-08-27 19:57 320K 
[ ]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2.pdf2025-08-19 19:14 354K 
[IMG]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2_Fig1.png2025-08-09 21:52 349K 
[IMG]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2_Fig2.png2025-08-09 21:52 754K 
[IMG]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2_T3.png2025-08-09 21:52 349K 
[IMG]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2_Table1.png2025-08-09 21:52 396K 
[IMG]Clinical-Application-Aripiprazole-Monohydrate-injectable-Schizophrenia-Consensus-Report-JCP-PLUNLAI2424AH2_Table2.png2025-08-09 21:52 169K 
[IMG]Correll-Headshot-copy-square.png2025-08-09 23:24 1.0M 
[ ]Effects-Alcohol-Use-Cognition-Individuals-Neurocognitive-Disorders-24m15738-SM.pdf2025-08-05 09:33 571K 
[ ]Five-Year-Outcomes-First-Suicide-Attempts-Lethality-Recurrence-Mortality-SM-24m15754.pdf2025-08-29 14:28 412K 
[IMG]HLX-TNS-22500_A-Potential-Paradigm-Shift_InfoGraphic_DR.png2025-08-10 02:31 52K 
[IMG]HLX-TNS-22500_Distinguishing-Features_Table_DR.png2025-08-10 02:31 98K 
[IMG]HLX-TNS-22500_How-satisfied-are-providers-and-patients_InfoGraphic_DR.png2025-08-10 02:31 135K 
[IMG]HLX-TNS-22500_Most-Injection-Site-AEs_Table_DR.png2025-08-10 02:31 74K 
[IMG]HLX-TNS-22500_Plasma-Levels-of-Active-Drug_Chart_DR.png2025-08-10 02:31 146K 
[IMG]HLX-TNS-22500_Relapse-Has-Devastating-Consequences_InfoGraphic_DR.png2025-08-10 02:31 79K 
[IMG]HLX-TNS-22500_Schizophrenia-Patient-Flow_InfoGraphic_DR.png2025-08-10 02:31 166K 
[IMG]HLX-TNS-22500_The-Systemic-Safety-Profile_Table_DR.png2025-08-10 02:31 98K 
[IMG]HLX-TNS-22500_UZEDY-utilizes-SteadyTeq_InfoGraphic_DR.png2025-08-10 02:31 60K 
[IMG]HLX-TNS-22500_What-are-the-dosing-intervals_InfoGraphic_DR.png2025-08-10 02:31 76K 
[IMG]HLX-TNS-22500_What-are-the-efficacy-results_InfoGraphic_DR.png2025-08-10 02:31 70K 
[IMG]JCP_AI-in-Depression.jpg2025-08-22 20:17 192K 
[IMG]JCP_Ascertain-TRD.jpg2025-08-08 17:25 99K 
[IMG]JCP_Cognitive-Impairment-Schizophrenia.jpg2025-08-08 17:25 73K 
[IMG]JCP_Delineating-the-Effects-of-Alcohol-Use.jpg2025-08-05 18:59 112K 
[IMG]JCP_Diverse-Sample-of-Women-with-Mood-Disorders.jpg2025-08-05 19:02 176K 
[IMG]JCP_LAIs-for-Bipolar-I.jpg2025-08-08 17:25 102K 
[IMG]JCP_LAIs-for-Schizophrenia.jpg2025-08-08 17:25 67K 
[IMG]JCP_Levomilnacipran-not-Duloxetine.jpg2025-08-22 20:17 182K 
[IMG]JCP_Lumateperone.jpg2025-08-22 20:17 141K 
[IMG]JCP_N-acetylcysteine-for-PTSD-and-Alcohol-Use.jpg2025-08-22 20:17 89K 
[IMG]JCP_Rapid-Onset-Efficacy-of-Onfasprodil.jpg2025-08-05 19:02 99K 
[IMG]JCP_Superiority-of-Clozapine.jpg2025-08-22 20:17 108K 
[IMG]Jenny-Guidi-PhD-photo-2022-bis.jpg2025-08-25 20:33 135K 
[IMG]Ketter-Terence-photo.jpg2025-08-15 16:20 263K 
[ ]Lumateperone-Adjunctive-Therapy-Patients-With-Major-Depressive-Disorder-Randomized-Double-Blind-Phase-3-Trial-25m15848-SM.pdf2025-08-22 10:57 354K 
[IMG]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803-f1.png2025-08-26 09:03 84K 
[IMG]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803-f2.png2025-08-26 09:03 154K 
[IMG]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803-t1.png2025-08-26 20:45 163K 
[IMG]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803-t2.png2025-08-26 09:03 87K 
[IMG]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803-t3.png2025-08-26 09:03 104K 
[ ]N-acetylcysteine-co-occurring-posttraumatic-stress-disorder-alcohol-use-disorder-double-blind-randomized-controlled-trial-25m15803.pdf2025-08-26 09:01 3.6M 
[ ]Onfasprodil-Phase-2-TRD-Study-JCP-23m15246-PDF.pdf2025-08-05 22:57 2.3M 
[ ]Onfasprodil-Phase-2-TRD-Study-JCP-23m15246-SM.pdf2025-08-05 22:57 382K 
[IMG]PCC_Beyond-the-Brain.jpg2025-08-05 03:06 109K 
[IMG]PCC_Catatonia-in-Pregnancy.jpg2025-08-22 20:17 97K 
[IMG]PCC_Cerebral-Amyloid-Angiopathy.jpg2025-08-07 01:59 125K 
[IMG]PCC_Depression-Remission.jpg2025-08-22 20:17 92K 
[IMG]PCC_Functional-Neurological-Management.jpg2025-08-18 18:32 96K 
[IMG]PCC_Gastrointestinal-Complications-of-Clozapine.jpg2025-08-07 01:59 101K 
[IMG]PCC_Improving-Dementia-Care.jpg2025-08-07 01:59 172K 
[IMG]PCC_Menstrual-Psychosis.jpg2025-08-18 18:32 200K 
[IMG]PCC_PTSD-In-Primary-Care-Practices.jpg2025-08-05 03:02 124K 
[IMG]PCC_Severe-Psychosis-Cushing-Syndrome.jpg2025-08-18 18:32 133K 
[IMG]PCC_Sudden-Confusion-in-a-Patient.jpg2025-08-07 02:02 166K 
[IMG]PCC_Tick-borne-disease.jpg2025-08-08 17:25 60K 
[ ]PSI-Position-Statement.pdf2025-08-15 17:16 44K 
[IMG]PSI-Response-statement.jpg2025-08-15 17:13 1.0M 
[IMG]Point-Improvement-from-Baseline-to-End-of-Treatment-3.png2025-08-27 14:48 104K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM-1.pdf2025-08-04 15:25 382K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM-2.pdf2025-08-05 12:51 382K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM-3.pdf2025-08-05 12:53 382K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM-4.pdf2025-08-05 12:59 382K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM-5.pdf2025-08-05 13:01 382K 
[ ]Rapid-Onset-Sustained-Efficacy-Onfasprodil-MIJ821-Novel-NR2B-Negative-Allosteric-Modulator-Patients-Treatment-Resistant-Depression-Phase-2-Randomized-Placebo-Controlled-Proof-of-Concept-Study-23m15246-SM.pdf2025-08-04 15:17 382K 
[IMG]Teva_Logo_RGB.png2025-08-10 02:31 21K 
[IMG]UZEDYR_Doses_Logo_RGB.png2025-08-10 02:31 55K 
[ ]VEGF-other-biomarkers-cognition-first-episode-psychosis-24m15486.pdf2025-08-11 12:54 4.1M 
[IMG]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899-t1.png2025-08-01 05:18 70K 
[IMG]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899-t2.png2025-08-01 05:18 63K 
[IMG]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899-t3.png2025-08-01 05:18 103K 
[IMG]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899-t4.png2025-08-01 05:18 143K 
[IMG]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899-t5.png2025-08-01 05:18 112K 
[ ]assessment-management-posttraumatic-stress-disorder-primary-care-practices-24f03899.pdf2025-08-01 05:18 3.6M 
[IMG]cerebral-amyloid-angiopathy-psychotic-disorder-25cr03964-f1.png2025-08-07 15:14 364K 
[IMG]cerebral-amyloid-angiopathy-psychotic-disorder-25cr03964-t1.png2025-08-07 15:14 81K 
[ ]cerebral-amyloid-angiopathy-psychotic-disorder-25cr03964.pdf2025-08-07 11:59 1.9M 
[IMG]clinical-application-aripiprazole-monohydrate-lais-bipolar-disorder-consensus-report-P-LUN-LAI-2424-BDI-Fig1.png2025-08-08 17:33 816K 
[IMG]clinical-application-aripiprazole-monohydrate-lais-bipolar-disorder-consensus-report-P-LUN-LAI-2424-BDI-Fig2.png2025-08-08 17:33 1.8M 
[IMG]clinical-application-aripiprazole-monohydrate-lais-bipolar-disorder-consensus-report-P-LUN-LAI-2424-BDI-Fig3.png2025-08-08 17:33 1.3M 
[ ]clinical-application-aripiprazole-monohydrate-lais-bipolar-disorder-consensus-report-PLUNLAI2424AH3.pdf2025-08-12 19:12 924K 
[IMG]comparative-effectiveness-research-trial-antidepressant-incomplete-non-responders-treatment-resistant-depression-ASCERTAIN-TRD-effect-aripiprazole-repetitive-transcranial-magnetic-stimulation-augmenta24m15614-f1-1.png2025-08-08 10:33 31K 
[IMG]comparative-effectiveness-research-trial-antidepressant-incomplete-non-responders-treatment-resistant-depression-ASCERTAIN-TRD-effect-aripiprazole-repetitive-transcranial-magnetic-stimulation-augmenta24m15614-f1.png2025-08-08 10:32 31K 
[IMG]comparative-effectiveness-research-trial-antidepressant-incomplete-non-responders-treatment-resistant-depression-ASCERTAIN-TRD-effect-aripiprazole-repetitive-transcranial-magnetic-stimulation-augmenta24m15614-f2-1.png2025-08-08 10:33 69K 
[IMG]comparative-effectiveness-research-trial-antidepressant-incomplete-non-responders-treatment-resistant-depression-ASCERTAIN-TRD-effect-aripiprazole-repetitive-transcranial-magnetic-stimulation-augmenta24m15614-f2.png2025-08-08 10:32 69K 
[ ]comparative-effectiveness-research-trial-antidepressant-incomplete-non-responders-treatment-resistant-depression-ASCERTAIN-TRD-effect-aripiprazole-repetitive-transcranial-magnetic-stimulation-augmenta24m15614.pdf2025-08-08 09:25 3.6M 
[ ]comparing-cognitive-effects-repeated-intravenous-ketamine-electroconvulsive-therapy-in-patients-treatment-resistant-depression-secondary-analysis-ELEKT-D-trial-25m15781.pdf2025-09-01 01:20 3.5M 
[IMG]depression-remission-response-anxiety-predictor-ECT-25m03939-f1.png2025-08-26 06:34 112K 
[ ]depression-remission-response-anxiety-predictor-ECT-25m03939.pdf2025-08-26 06:34 3.2M 
[IMG]effects-alcohol-use-cognition-individuals-neurocognitive-disorders-f1.png2025-08-04 14:57 69K 
[IMG]effects-alcohol-use-cognition-individuals-neurocognitive-disorders-t1.png2025-08-04 14:57 68K 
[IMG]effects-alcohol-use-cognition-individuals-neurocognitive-disorders-t2.png2025-08-04 14:57 62K 
[IMG]effects-alcohol-use-cognition-individuals-neurocognitive-disorders-t3.png2025-08-04 14:57 172K 
[IMG]effects-october-7-2023-terrorist-attack-ptsd-depression-anxiety-suicidal-ideation-distinct-exposure-groups-25m15970-f1.png2025-08-30 11:42 88K 
[IMG]effects-october-7-2023-terrorist-attack-ptsd-depression-anxiety-suicidal-ideation-distinct-exposure-groups-25m15970-t1.png2025-08-30 11:42 93K 
[IMG]effects-october-7-2023-terrorist-attack-ptsd-depression-anxiety-suicidal-ideation-distinct-exposure-groups-25m15970-t2.png2025-08-30 11:42 100K 
[IMG]effects-october-7-2023-terrorist-attack-ptsd-depression-anxiety-suicidal-ideation-distinct-exposure-groups-25m15970-t3.png2025-08-30 11:42 110K 
[IMG]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754-f1.png2025-08-29 09:06 67K 
[IMG]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754-f2.png2025-08-29 09:06 70K 
[IMG]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754-t1.png2025-08-29 09:06 175K 
[IMG]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754-t2.png2025-08-29 09:06 68K 
[IMG]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754-t3.png2025-08-29 09:06 62K 
[ ]five-year-outcomes-first-suicide-attempts-lethality-recurrence-mortality-24m15754.pdf2025-08-29 14:48 1.0M 
[IMG]gastrointestinal-complications-clozapine-treatment-assessment-management-25f03984-t1.png2025-08-08 08:53 62K 
[ ]gastrointestinal-complications-clozapine-treatment-assessment-management-25f03984.pdf2025-08-07 15:27 3.2M 
[ ]improving-dementia-care-northern-Kerala-25br03938.pdf2025-08-06 09:44 962K 
[IMG]in-memoriam-terence-a-ketter-md-JCP-25f16060.jpg2025-08-15 16:39 125K 
[ ]in-memoriam-terence-a-ketter-md-JCP-25f16060.pdf2025-08-15 16:16 313K 
[IMG]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867-f1.png2025-08-22 11:59 37K 
[IMG]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867-f2.png2025-08-22 11:59 43K 
[IMG]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867-f3.png2025-08-22 11:59 41K 
[IMG]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867-f4.png2025-08-22 11:59 41K 
[IMG]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867-f5.png2025-08-22 11:59 38K 
[ ]levomilnacipran-not-duloxetine-inhibits-serotonin-norepinephrine-reuptake-throughout-therapeutic-range-25m15867.pdf2025-08-22 11:58 3.2M 
[IMG]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848-f1.png2025-08-22 10:42 111K 
[IMG]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848-t1.png2025-08-22 10:42 107K 
[IMG]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848-t2.png2025-08-22 10:42 168K 
[IMG]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848-t3.png2025-08-22 10:42 56K 
[IMG]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848-t4.png2025-08-22 10:42 85K 
[ ]lumateperone-adjunctive-therapy-patients-with-major-depressive-disorder-randomized-double-blind-phase-3-trial-25m15848.pdf2025-08-22 10:42 3.5M 
[IMG]management-functional-neurological-disorder-25f03975-t1.png2025-08-18 07:18 115K 
[IMG]management-functional-neurological-disorder-25f03975-t2.png2025-08-18 07:18 178K 
[ ]management-functional-neurological-disorder-25f03975.pdf2025-08-21 08:39 1.8M 
[ ]management-neurobehavioral-symptoms-Machado-Joseph-disease-25cr03955.pdf2025-08-30 12:54 945K 
[ ]multidisciplinary-approach-catatonia-pregnancy-25cr03966.pdf2025-08-22 23:52 2.6M 
[IMG]neuropsychiatric-manifestation-tick-borne-disease-importance-screening-endemic-regions-25cr03948-f1.png2025-08-08 07:40 93K 
[ ]neuropsychiatric-manifestation-tick-borne-disease-importance-screening-endemic-regions-25cr03948.pdf2025-08-08 07:40 1.0M 
[ ]psychedelic-therapies-one-drug-multiple-treatments-reply-modesto-lowe-et-al-25lr15978a.pdf2025-08-29 14:06 938K 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-1.pdf2025-08-04 10:14 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-2.pdf2025-08-04 15:16 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-3.pdf2025-08-04 15:18 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-4.pdf2025-08-04 15:20 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-5.pdf2025-08-04 15:23 1.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-6.pdf2025-08-05 10:03 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246-7.pdf2025-08-05 10:03 2.3M 
[ ]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-23m15246.pdf2025-08-04 10:14 2.3M 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-f1.png2025-08-04 11:01 253K 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-f2.png2025-08-04 11:01 101K 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-f3.png2025-08-04 11:01 202K 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-t1.png2025-08-04 11:01 125K 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-t2.png2025-08-04 11:01 43K 
[IMG]rapid-onset-sustained-efficacy-onfasprodil-MIJ821-novel-NR2B-negative-allosteric-modulator-patients-treatment-resistant-depression-phase-2-randomized-placebo-controlled-proof-of-concept-study-t3.png2025-08-04 11:01 100K 
[ ]severe-psychosis-Cushing-syndrome-25cr03957.pdf2025-08-18 11:19 845K 
[ ]sudden-confusion-patient-treated-divalproex-25cr03950.pdf2025-08-06 10:11 897K 
[IMG]superiority-clozapine-over-second-generation-antipsychotics-patients-treatment-resistant-schizophrenia-25f16038-t1.png2025-08-22 12:16 83K 
[IMG]superiority-clozapine-over-second-generation-antipsychotics-patients-treatment-resistant-schizophrenia-25f16038-t2.png2025-08-22 12:16 58K 
[IMG]superiority-clozapine-over-second-generation-antipsychotics-patients-treatment-resistant-schizophrenia-25f16038-t3.png2025-08-22 12:16 67K 
[IMG]superiority-clozapine-over-second-generation-antipsychotics-patients-treatment-resistant-schizophrenia-25f16038-t4.png2025-08-22 12:16 139K 
[ ]superiority-clozapine-over-second-generation-antipsychotics-patients-treatment-resistant-schizophrenia-25f16038.pdf2025-08-21 19:37 3.3M 
[ ]toward-consensus-psychedelic-assisted-therapy-critical-role-psychotherapeutic-support-25lr15978.pdf2025-08-29 06:10 835K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-f1.png2025-08-05 10:19 28K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-t1.png2025-08-05 10:19 50K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-t2.png2025-08-05 10:19 47K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-t3.png2025-08-05 10:19 47K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-t4.png2025-08-05 10:19 50K 
[IMG]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823-t5.png2025-08-05 10:19 20K 
[ ]treatment-use-preference-diverse-sample-women-mood-disorders-25m15823.pdf2025-08-05 10:42 1.8M 
[IMG]two-cases-menstrual-psychosis-25cr03943-t1.png2025-08-26 13:36 79K 
[ ]two-cases-menstrual-psychosis-25cr03943.pdf2025-08-26 13:13 1.1M 
[IMG]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794-f1.png2025-08-08 04:21 128K 
[IMG]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794-f2.png2025-08-08 04:21 73K 
[IMG]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794-t1.png2025-08-08 04:21 176K 
[IMG]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794-t2.png2025-08-08 04:21 191K 
[IMG]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794-t3.png2025-08-08 04:21 61K 
[ ]understanding-characteristics-burden-cognitive-impairments-schizophrenia-US-medical-expenditure-panel-survey-25m15794.pdf2025-08-08 04:21 3.5M 
[IMG]unilateral-abdominal-seizures-manifestation-neurocysticercosis-25cr03926-f1.png2025-08-04 11:08 165K 
[IMG]unilateral-abdominal-seizures-manifestation-neurocysticercosis-25cr03926-f2.png2025-08-04 11:08 150K 
[ ]v76n0208-SM.pdf2025-08-11 18:49 183K 
[ ]v76n0208.pdf2025-08-11 18:49 477K 
Apache/2.4.65 (Ubuntu) Server at www.psychiatrist.com Port 443